Using PSA Doubling Time to Predict Metastatic Prostate Cancer

Video
Conference|American Society of Clinical Oncology Annual Meeting (ASCO)

Nancy Dawson, MD, discusses PSA dynamics: the significance of PSA levels and PSA doubling time-the marker which currently provides the most information-and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.

Nancy Dawson, MD, discusses PSA dynamics: the significance of PSA levels and PSA doubling time-the marker which currently provides the most information-and their usefulness in predicting metastatic disease and in counseling patients on their prognosis.

Recent Videos
Co-hosts Kristie L. Kahl and Andrew Svonavec highlight what to look forward to at the 2025 ESMO Annual Congress, from hot topics and emerging trends to travel recommendations.
A new clinical trial aims to offer a novel allogenic CAR T-cell product for patients with lymphoma closer to home.
Unique toxicities presented with talquetamab tend to get progressively better as the treatment course continues, according to Prerna Mewawalla, MD.
Modification of REMS programs may help patients travel back to community practices sooner, according to Suman Kambhampati, MD.
Symposiums and regional meetings may expand knowledge of how to adopt novel CAR T-cell therapies and bispecific antibodies, said Suman Kambhampati, MD.
Prophylactic steroid or tocilizumab use may help in preventing CRS in patients undergoing treatment with bispecific antibodies for multiple myeloma.
Related Content
Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.

Salvage Nodal Radiation Shows Tolerability, Low Toxicity in Prostate Cancer

Roman Fabbricatore
October 8th 2025
Article

Imaging developments have made it possible to detect nodal recurrence at low PSA levels, which could help guide salvage approaches for prostate cancer.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Navigating AE Management for Cellular Therapy Across Hematologic Cancers

Tiba Al Sagheer, PharmD, BCOP, BCACP;Rebecca Gonzalez, PharmD, BCOP, FASTCT;Syeda Saba Kareem PharmD, BCOP
August 11th 2025
Podcast

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

CRS onset typically occurred within 12 hours after tarlatamab infusion and was resolved with antipyretics for fever and intravenous fluids.

Tarlatamab Requires Strategic Toxicity Monitoring and Management in ES-SCLC

Tim Cortese
October 2nd 2025
Article

A real-world, retrospective analysis showed that CRS and ICANS occurred in 48% and 16% of patients with ES-SCLC who were treated with tarlatamab.

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Key Advances Across Kidney Cancer Research and Management at KCRS 2025

Thomas Powles, MBBS, MCRP, MD;David Braun, MD, PhD;Wenxin (Vincent) Xu, MD;Eric Jonasch, MD
July 28th 2025
Podcast

Experts share their perspectives on updated clinical trial results, personalized cancer vaccine research, and other notable developments in kidney cancer.

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

Proton Vs Photon Therapy Yields Similar HRQOL in Non-Metastatic Breast Cancer

Ariana Pelosci
September 30th 2025
Article

The RadComp Consortium trial showed comparable HRQOL between proton and photon therapy for patients with non-metastatic breast cancer.

Overall urinary toxicity was not significantly improved with SBRT vs moderately hypofractionated IMRT.

SBRT Reduces Bowel Toxicity vs IMRT in Intermediate-Risk Prostate Cancer

Tim Cortese
September 30th 2025
Article

SBRT achieved a 5-year DFS rate of 89% vs 92% with moderately hypofractionated IMRT in patients with intermediate-risk prostate cancer.